生物制药公司云顶新耀近日于港交所成功上市，募资金额为32.8亿港元。中伦律师事务所、世达国际律师事务所担任发行人律师，天元律师事务所、凯易律师事务所则为联席保荐人提供法律意见。
2017年7月由康桥资本投资设立，云顶新耀致力于创新药开发及商业化，其目前在研产品涉及肿瘤、免疫学、心肾疾病以及感染性疾病，针对市场为大中华地区及亚太地区其他新兴市场。
这是继嘉和生物后，本月第二个登陆香港资本市场的生物医药公司。此次上市联席保荐人为高盛和美银证券。
中伦团队牵头律师为合伙人赵靖、陈芳、贾海波、高欣，同时得到非权益合伙人高如枫律师协助。
Skadden, Kirkland advise on Chinese biotech firm’s $451 million HK IPO
Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.
Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercialises potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.
It is the second Chinese biopharmaceutical company to go public in Hong Kong this month, after JHBP (CY) Holdings.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
